Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker Publication Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker Certara2018 年 2 月 8 日
Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial Publication Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial Certara2018 年 1 月 15 日
Model-informed Drug Development for Malaria Therapeutics Publication Model-informed Drug Development for Malaria Therapeutics Certara2018 年 1 月 6 日
How to Perform Level C IVIVC in Phoenix On-Demand Webinar 如何在 Phoenix 中执行 C 级 IVIVC C 级 IVIVC 研究分步指导。Certara2017 年 12 月 13 日
Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Publication Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Certara2017 年 11 月 1 日
A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies Publication A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies Certara2017 年 10 月 30 日
Influence of Molecular Size on the Clearance of Antibody Fragments Publication Influence of Molecular Size on the Clearance of Antibody Fragments Certara2017 年 10 月 1 日
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal White Paper 药物资产评估:提高交易的 "成功概率” Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…Certara2017 年 8 月 24 日
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Publication Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Certara2017 年 8 月 1 日
Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Publication Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Certara2017 年 7 月 15 日